The Novel Use of Very High Doses of Cabergoline and a Combination of Testosterone and an Aromatase Inhibitor in the Treatment of a Giant Prolactinoma
Authors:
- 1 October 2002
- journal article
- case report
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 87 (10) , 4447-4451
Abstract
Most prolactinomas respond rapidly to low doses of dopamine agonists. Occasionally, stepwise increases in doses of these agents are needed to achieve gradual prolactin (PRL) reductions. Approximately 50% of treated men remain hypogonadal, yet testosterone replacement may stimulate hyperprolactinemia. A 34-yr-old male with a pituitary macroadenoma was found to have a PRL level of 10,362 micro g/liter and testosterone level of 3.5 nmol/liter. Eleven months of dopamine agonist therapy at standard doses lowered PRL levels to 299 micro g/liter. Subsequent stepwise increases in cabergoline (3 mg daily) further lowered PRL levels to 71 micro g/liter, but hypogonadism persisted. Initiation of testosterone replacement resulted in a rise and discontinuation in a fall of PRL levels. Aromatization of exogenous testosterone to estradiol and subsequent estrogen-stimulated PRL release was suspected. Concomitant use of cabergoline with the aromatase inhibitor anastrozole after resuming testosterone replacement resulted in the maintenance of testosterone levels and restoration of normal sexual function, without increasing PRL. Ultimately, further reduction in PRL on this therapy permitted endogenous testosterone production. Thus, novel pharmacological maneuvers may permit successful medical treatment of some patients with invasive macroprolactinomas.Keywords
This publication has 23 references indexed in Scilit:
- Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 PatientsThe Journal of Clinical Endocrinology & Metabolism, 1999
- Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's diseaseNeurology, 1996
- Cabergoline in Parkinson's diseaseNeurology, 1993
- Sex Steroid Control of Gonadotropin Secretion in the Human Male. II. Effects of Estradiol Administration in Normal and Gonadotropin-Releasing Hormone-Deficient Men*The Journal of Clinical Endocrinology & Metabolism, 1991
- Sex Steroid Control of Gonadotropin Secretion in the Human Male. I. Effects of Testosterone Administration in Normal and Gonadotropin-Releasing Hormone-Deficient Men*The Journal of Clinical Endocrinology & Metabolism, 1991
- Transcriptional Regulation by Estrogen of Episomal Prolactin Gene Regulatory ElementsMolecular Endocrinology, 1989
- Bromocriptine as Primary Therapy for Prolactin-Secreting Macroadenomas: Results of a Prospective Multicenter Study*The Journal of Clinical Endocrinology & Metabolism, 1985
- Prolactin secretion in the human male is increased by endogenous oestrogens and decreased by exogenous/endogenous androgensInternational Journal of Andrology, 1984
- Prolactin-Secreting Tumors and Hypogonadism in 22 MenNew England Journal of Medicine, 1978
- Potent Antidopaminergic Activity of Estradiol at the Pituitary Level on Prolactin ReleaseScience, 1978